Radiotherapy for recurrent prostate cancer: 2018 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group

Hester Lieng*, Amy J. Hayden, David R.H. Christie, Brian J. Davis, Thomas N. Eade, Louise Emmett, Tanya Holt, George Hruby, David Pryor, Thomas P. Shakespeare, Mark Sidhom, Marketa Skala, Kirsty Wiltshire, John Yaxley, Andrew Kneebone

*Corresponding author for this work

Research output: Contribution to journalReview articleResearchpeer-review

24 Citations (Scopus)

Abstract

The management of patients with biochemical, local, nodal, or oligometastatic relapsed prostate cancer has become more challenging and controversial. Novel imaging modalities designed to detect recurrence are increasingly used, particularly PSMA-PET scans in Australia, New Zealand and some European countries. Imaging techniques such as MRI and PET scans using other prostate cancer-specific tracers are also being utilised across the world. The optimal timing for commencing salvage treatment, and the role of local and/or systemic therapies remains controversial. Through surveys of the membership, the Australian and New Zealand Faculty of Radiation Oncology Genito-Urinary Group (FROGG) identified wide variation in the management of recurrent prostate cancer. Following a workshop conducted in April 2017, the FROGG management committee reviewed the literature and developed a set of recommendations based on available evidence and expert opinion, for the appropriate investigation and management of recurrent prostate cancer. These recommendations cover the role and timing of post-prostatectomy radiotherapy, the management of regional nodal metastases and oligometastases, as well as the management of local prostate recurrence after definitive radiotherapy.

Original languageEnglish
Pages (from-to)377-386
Number of pages10
JournalRadiotherapy and Oncology
Volume129
Issue number2
DOIs
Publication statusPublished - Nov 2018

Fingerprint

Dive into the research topics of 'Radiotherapy for recurrent prostate cancer: 2018 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group'. Together they form a unique fingerprint.

Cite this